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Abstract
In Chuvash polycythemia, a homozygous 598C>T mutation in the von Hippel-Lindau gene (VHL)
leads to an R200W substitution in VHL protein, impaired degradation of α-subunits of hypoxia
inducible factor (HIF)-1 and HIF-2, and augmented hypoxic responses during normoxia. Chronic
hypoxia of high altitude is associated with decreased serum glucose and insulin concentrations.
Other investigators reported that HIF-1 promotes cellular glucose uptake by increased expression
of GLUT1 and increased glycolysis by increased expression of enzymes such as PDK. On the
other hand, inactivation of Vhl in murine liver leads to hypoglycemia associated with a HIF-2-
related decrease in the expression of the gluconeogenic enzymes genes Pepck, G6pc, and Glut2.
We therefore hypothesized that glucose concentrations are decreased in individuals with Chuvash
polycythemia. We found that 88 Chuvash VHLR200W homozygotes had lower random glucose and
glycosylated hemoglobin A1c levels than 52 Chuvash subjects with wildtype VHL alleles. Serum
metabolomics revealed higher glycerol and citrate levels in the VHLR200W homozygotes. We
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expanded these observations in VHLR200W homozygote mice and found that they had lower
fasting glucose values and lower glucose excursions than wild-type control mice but no change in
fasting insulin concentrations. Hepatic expression of Glut2 and G6pc but not Pdk2 was decreased
and skeletal muscle expression of Glut1, Pdk1 and Pdk4 was increased. These results suggest that
both decreased hepatic gluconeogenesis and increased skeletal uptake and glycolysis contribute to
the decreased glucose concentrations. Further study is needed to determine whether
pharmacologically manipulating HIF expression might be beneficial for treatment of diabetic
patients.
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Introduction
Hypoxia inducible factor (HIF)-1 and HIF-2 are transcription factors that play a major role
in cellular responses to hypoxia. Levels of the α subunits of HIFs are tightly controlled.
These transcription factors are constantly degraded under normoxia by the proteosome
through an iron-requiring interaction with their negative regulator, pVHL [1]. Proline
hydroxylation of HIF-α by prolyl hydroxylase domain (PHD) enzymes, a process that
requires oxygen and iron, is required for the interaction of HIF-α with VHL protein [2].
During hypoxia this process is inhibited, leading to accumulation of HIFs as HIF-α subunits
translocate to the nucleus and interact with HIF-1β to form heterodimers. Subsequently,
these heterodimeric transcription factors bind to key hypoxia response elements, thereby
governing the transcription of genes that regulate adaptation to hypoxia [3]. Chuvash
polycythemia is an autosomal recessive congenital disorder characterized by a homozygous
598C>T mutation in the VHL gene resulting in an R200W amino acid change in the VHL
protein [4]. It is characterized by augmented HIF-1α and HIF-2α levels during normoxia
and altered expression of erythropoietin, glucose transporter-1 and a number of other genes
[4-6].
Chronic hypoxia of high altitude is associated with decreased serum glucose and insulin
concentrations [7, 8]. A variety of mechanisms might explain this phenomenon, including
enhanced cellular glucose uptake, glycolysis and glycogenesis related to increased HIF-1
expression [9-11] and decreased hepatic gluconeogenesis related to increased HIF-2
expression [12, 13]. Because of the upregulation of HIFs levels during normoxia that
characterizes homozygosity for the germline VHLR200W mutation, we sought to determine
changes in glucose metabolism in Chuvash polycythemia patients. We measured random
blood glucose concentrations, determined glycosylated hemoglobin (HbA1c) levels and
assessed the patients’ body mass index (BMI), serum cholesterol, triglyceride levels and
several other metabolic intermediates. Finally, we explored potential mechanisms of altered
glucose metabolism in VHLR200W mice.
Materials and Methods
Study subjects
The Institutional Review Board of Howard University approved the study and the
participants provided written informed consent. Individuals >20 years of age with a
diagnosis of familial polycythemia or controls without such a diagnosis were studied in
Chuvashia, Russia. Genotyping for the VHLR200W mutation was performed as previously
described.[5] The clinical characteristics for the study subjects and the controls including
their gender, age, and BMI were recorded.
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Laboratory studies
The complete blood count was performed by an automated analyzer (Sysmex XT 2000i,
Sysmex Corporation, Kobe, Hyogo, Japan). Serum ferritin concentration was determined by
enzyme immunoassay (Ramco Laboratories Inc., Stafford, TX). Serum glucose, bilirubin,
creatinine, BUN, triglyceride and cholesterol concentrations were determined by Quest
Diagnostics (Auburn Hills, MI) in an Olympus 2700 analyzer (Olympus Optical Co. Ltd,
Shizuoka-ken, Japan).
HbA1c level was determined by high performance liquid chromatography (HPLC) using the
Primus Diagnostics ultra2 with Resolution™ Software Analytical System for
Hemoglobinopathies, commercialized by Trinity Biotech, New Jersey, USA. Samples were
processed using the high-resolution method, which requires close to 11 minutes of run time
per sample, allowing for higher sensitivity and specificity in detection. The results from
samples where the HbA1c peak was not resolved were excluded from the analysis. The
HPLC column used in this study is designed for the assessment of hemoglobinopathies and
is not the column recommended by the manufacturer for the optimal evaluation of HbA1c.
Metabolomics Analysis
To ensure metabolite volatility for gas chromatographic analysis each sample underwent a
two-step derivatization process. The extracted metabolites were suspended in 30 μL of
pyridine containing O-methylhydroxylamine (20 mg/mL) and transferred to a 1 mL Recti-
Vial (Pierce) fitted with a Teflon cap. The mixture was subjected to microwave irradiation
for 30 seconds followed by the addition of 30 μL of N-methyl-N-
trimethylsilyltrifluoroacdtamide + 1% trimethylchlorosilane (Pierce) and incubated at 37°C
for thirty minutes then transferred to an auto sampler vial containing 70 μL of heptane and
analyzed by GC-MS. An Agilent 7683 auto injector was employed to inject 1 μL of each
sample into an injector. The injector was set to a 1:1 split ratio and the temperature was held
at 250°C. An Agilent 6890 gas chromatograph was used for analysis. A Restek 30 m
Rtx-5MS with a 10 m guard column was employed for separation. Helium was used as the
carrier gas at a 1 mL/min flow rate. The transfer line into the mass spectrometer was held at
250°C. A MicroMass GCT Premier (Waters, Milford, MA) was used for mass spectrometric
analysis. Normal 70 eV electron impact conditions were used for fragmentation. Data were
recorded using MassLynx (Waters, Milford, MA). Sample data were divided into two
analysis groups, the first was used to build a model of metabolic differences and the second
used to test for model robustness. Chromatographic peak detection and height analysis for
each chromatogram was performed using MarkerLynx (Waters, Milford, MA). To find
possible variation in each sample group the data were transferred to SIMCA-P+ ver.11.5
(Umetrics, Kinnelon, NJ) where principal component analysis (PCA) and partial least
squares-discriminate analysis (PLS-DA) were performed. This produced a possible list of
metabolites that differed between the groups. Each metabolite was investigated to determine
if these changes were real. The chromatographic area for each metabolite was integrated and
recorded. Student’s t-test was used to test for significance. This was performed twice using
two separate characteristic mass peaks for analysis.
Animal Studies
VHLR200W homozygous mice on a C57BL6 background and wild-type littermates were
generated and maintained as previously described [6]. The mice were back-crossed onto the
C57BL6 background for more than six generations. The animal experimentation conformed
to protocols approved by the animal care committees of the University of Utah. VHLR200W
homozygous mice and age-matched wild-type littermates between 4 and 8 months of age
were euthanized, then dissected to remove the liver. Total RNA was extracted from livers
and skeletal muscle using Trizol (Molecular Research Center, Cincinnati, OH). To quantify
McClain et al. Page 3
J Mol Med (Berl). Author manuscript; available in PMC 2014 January 01.
$watermark-text
$watermark-text
$watermark-text
G6pc, Glut1, Glut2, Glut4, Pepck, Pdk2 and Pdk4 mRNA levels, hepatic and skeletal muscle
RNA (500 ng) was reverse-transcribed into cDNA using SuperScript II with oligo dT primer
according to the manufacturer’s instructions (Invitrogen,Carlsbad, CA) and 2μl of cDNA
was used for real-time PCR using SYBR Green dye with specific primers (G-6-Pase: 5′-
CTTGTACCTGAAAGCCTTGG-3′ and 5′-GTCCCATGAACTTGCTGA TG-3′; Glut4:
5′-CACCAACTCCAGCCAAACTC-3′ and 5′-GAGGTAAAGGGAAAGGGGAAA-3′;
Glut1: 5′-GCTGGGAATCGTCGTTGG-3′ and 5′-GATGGGCTGGCGGTAGG-3′; Pdk1:
5′-TTACTCAGTGGAACACCGCC-3′ and 5′-CATGAGAGCGACCATGGAG-3′; Pdk2:
5′-TGACAGGGCTTTCTGGTCTT-3′ and 5′-GGAGATTGACATCCTGCCTG-3′; 18S:
5′-TTGACGGAAGGGCACCACCAG-3′ and 5′-GCACCACCACCCACGGAATCG-3′)
and the reaction was carried out at 50°C for 2 min,95°C for 10 min, followed by 50 cycles of
92°C for 15 s and 58°C for 1 min. ΔCt was expressed after normalization against 18S. Fold
change was calculated by the ΔΔCt method [14]. Pdk4 and Glut4 are not expressed in liver,
while Glut2 and Pdk2 are not expressed in muscle.
Glucose tolerance testing was performed after a 6 hr fast. Mice were injected
intraperitoneally (IP) with 1 mg/g body weight of glucose in 0.9% saline. Glucose levels
were measured from tail vein blood with a Glucometer (Elite, Bayer Corp., Tarrytown, NY)
at 0, 5, 15, 30, 60, and 120 min. Extra tail blood (30 μl) was collected at 0 and 30 min for
insulin measurement.
Statistical analysis
Continuous variables that followed a skewed distribution were transformed to normal
distribution by natural log or square root transformation. Distribution of clinical and
laboratory measurements were tested between VHLR200W homozygotes and controls by
students’ t-test or Chi-square. Laboratory measurements that were continuous variables were
examined with linear regression; Pearson and Spearman correlation were used to assess the
correlation between blood glucose, hemoglobin A1c and other variables in two groups.
Multiple linear regression analysis was applied to test the independent relationship of
clinical variables with blood glucose and hemoglobin A1c concentration. Models were
checked for assumptions. Analyses were done in Stata 10.1 (StataCorp, College Station,
TX).
Results
Serum glucose and hemoglobin A1c concentrations in Chuvash polycythemia patients
and Chuvash controls
The study population included 88 VHLR200W homozygotes and 52 VHL wildtype subjects.
The median (interquartile range) age was 44 (34-54) years. Eighty-four (60%) of the
subjects were females. Random serum glucose concentrations and hemoglobin A1c levels
were lower in VHLR200W homozygotes (Figure 1). Age, BMI, WBC count, and serum
concentrations of cholesterol and ferritin were also lower in VHLR200W homozygotes (Table
1). Hemoglobin concentration, and serum concentrations of bilirubin and triglyceride tended
to be greater in the VHLR200W homozygotes. Hemoglobin A1c correlated significantly with
the blood glucose concentration in both VHLR200W homozygotes and controls (Figure 1).
In univariate analyses among subjects stratified by VHL genotype, the most significant
positive correlations were those of systemic blood pressure and serum ferritin concentration
with hemoglobin A1c levels among the VHL wildtype subjects and BMI with serum glucose
concentration among VHLR200W homozygotes (Table 2).
In multiple linear regression models that adjusted for age, gender, BMI, and history of
smoking, serum glucose concentration and hemoglobin A1c level continued to be lower in
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VHLR200W homozygotes than controls (Table 3). After adjustment for these covariates and
based on the median values in the control group, VHLR200W homozygosity was associated
with an average 15 mg/dL decrease in the random glucose concentration (95% CI = 2-26)
and with an average 0.7 % decrease in hemoglobin A1c (95%CI = 0.2-1.2).
Metabolomic studies
To further investigate the metabolic changes in the VHLR200W homozygotes we performed
unbiased metabolomics analysis. Glycerol, phosphate, urea, and three unknowns were found
to be elevated in VHLR200W homozygote samples (Table 4). Unknown metabolites do not
correspond to our in-house developed metabolite library or the commercially available
National Institute of Standards and Technologies (NIST) 2.0 database and were excluded
from analysis. Citric acid had two very strong outliers (> 20 times the median and >2
standard deviations from the mean); however, we could not rule out the possibility that this
was caused by an interfering metabolite. If those are removed from the analysis, citric acid is
also elevated in VHLR200W homozygotes.
Chuvash polycythemia mice
Glucose tolerance testing was performed on male and female Chuvash polycythemia mice
and age matched wild-type C57BL6 controls. Both sexes of Chuvash polycythemia mice
had significantly lower fasting glucose values and glucose excursions than wild type mice
(Figure 2a). Despite the lower fasting glucose values, insulin levels did not differ between
the Chuvash polycythemia and wildtype mice (Figure 2b; P >0.6).
Realtime RT-PCR analysis of mRNAs from the livers of the Chuvash polycythemia mice
(Table 5) showed significant decreases at transcript levels of G6pc, encoding glucose-6-
phosphatase, decrease of Pepck, encoding phosphoenolpyrvate carboxykinase, enzymes that
are important in gluconeogenesis. There was no significant change in the transcript levels of
Pdk2, encoding pyruvate dehydrogenase kinase isoenzyme 2, or Glut1, two important
regulators of glucose transport and glycolysis, although the HIF-regulated Glut1 trended
toward an increase in the Chuvash polycythemia mice. In skeletal muscle, the tissue
responsible for most glucose uptake after glucose challenge, Glut1, Pdk1 and Pdk4 were
upregulated and there was a trend toward increased Glut4 expression. These data are
consistent with the lower glycemia in Chuvash mice related to decreased hepatic
gluconeogenesis and increased skeletal muscle glucose uptake and glycolysis.
Discussion
In this study we found that, similar to chronic hypoxia of high altitude, the homozygous
VHLR200W mutation is associated with a lower serum glucose concentration. These effects
were seen in both humans and a mouse model. We have probed the principal mechanisms
including hepatic glucose production, insulin levels, and peripheral glucose uptake
mechanisms, all of which are known to be affected by HIF pathway signaling. It should be
emphasized, however, that the regulation of plasma glucose concentrations is highly
complex, resulting from the interplay of several tissues (brain, muscle, fat, liver, gut,
pancreatic islets, and others) and several discrete pathways (insulin secretion, insulin
signaling, insulin-dependent and –independent glucose uptake, and multiple metabolic fates
of glucose). Without the analysis of multiple tissue-specific deletions of VHL and its
downstream targets that include the different HIF isoforms, it is impossible from the current
data to ascribe the changes in glucose to specific pathways in specific tissues. Furthermore,
all of the pathways enumerated above feed back upon one another, so any changes observed
in a tissue may be intrinsic to altered HIF pathway signaling but also to endocrine, nutrient,
or neural feedback based on HIF pathway signaling in other tissues. Nevertheless, the data
McClain et al. Page 5
J Mol Med (Berl). Author manuscript; available in PMC 2014 January 01.
$watermark-text
$watermark-text
$watermark-text
do offer suggestions as to the mechanisms by which VHLR200W affects metabolism. It
should be noted that a previous study found no significant difference in glucose tolerance
between humans with Chuvash polycythemia and controls, but the subjects in this relatively
small study (5 subjects and 5 controls) varied over a large range of ages and weights that
might have obscured any intergroup differences [15].
Among the several potential mechanisms whereby the upregulation of HIF-1 or HIF-2 in
VHLR200W homozygotes might lead to the reduction in serum glucose concentration are
changes in hepatic metabolism, as the liver is known to play a central role in maintaining
serum glucose concentrations by balancing the uptake of glucose from the circulation with
the release of glucose to the circulation via gluconeogenesis [16]. We observed decreased
hepatic expression of the glucose transporter Glut2 and the gluconeogenic gene glucose-6-
phosphatase (G6pc) and a trend to decreased expression of the rate-limiting enzyme in
gluconeogenesis phosphoenolpyruvate carboxykinase (Pepck), but not significantly
increased expression of Glut1 or Pdk2. These findings suggest that impairment of hepatic
gluconeogenesis contributes to the overall decline in glycemia in the Chuvash polycythemia
subjects. The results are consistent with the previous observation that HIF-2 decreases
hepatic gluconeogenesis [12, 13]. Namely, mice with Vhl-inactivated hepatocytes had
down-regulation of Glut2 and G6pc, leading to impaired release of glucose from the liver,
elevated hepatic glycogen storage and hypoglycemia [12]. The elevated plasma pyruvate
and lactate concentrations observed after a standard meal in five VHLR200W homozygotes
by other investigators [15] are consistent with such a scenario; pyruvate and lactate are
gluconeogenic precursors and their increased concentrations may result from a block in
gluconeogenesis. It should be noted that HIF-1 enhances hepatic glucose production during
hypoxia by activating PEPCK through direct binding of HIF-1 to the promoter region of the
PEPCK gene [17]. Thus, the observed effects in Chuvash polycythemia are more consistent
with an effect mediated by HIF-2.
In addition to effects on gluconeogenesis, enhanced HIF signaling also affects glycolysis
and glycogenesis in ways that would be expected to lower serum glucose and glycosylated
hemoglobin levels [9-11]. Specifically, HIF-1 enhances expression of the glucose
transporter, GLUT1 [9, 10], and the glycolytic enzymes, PDK [9] and LDHA [18]. PDK
inactivates pyruvate dehydrogenase, thus pushing pyruvate to lactate through the action of
LDHA rather than to mitochondrial oxidation. In turn, lactate is necessary to regenerate
NAD+ to re-feed the earlier steps in glycolysis. HIF-1 also promotes glycogenesis, or
increased production of glycogen from glucose in the liver and other tissues, by inducing
glycogen synthase-1 (GYS1) [11, 19] and protein phosphatase 1 regulatory subunit 3 C
(PPP1RsC) [20], which can lead to lowered glucose concentration [21].
In the current study, Chuvash polycythemia transgenic mice exhibited both decreased
fasting glycemia and decreased glucose excursions after glucose tolerance testing. These
results suggest that VHLR200W homozygotes experience lower glucose levels not only
because of changes in hepatic glucose production (a major determinant of fasting glucose
level) but also because of increased peripheral glucose utilization, which in the fed or
glucose-challenged state is primarily in skeletal muscle. Consistent with this hypothesis, in
skeletal muscle of the Chuvash polycythemia mouse model we observed up regulation of
Glut1, the basal (non-insulin-stimulated) glucose transporter, and a trend toward an increase
in Glut4, the insulin-stimulated transporter. Increased glucose utilization would also be
expected to contribute to the observed high lactate levels by increased production, adding to
the decreased utilization of lactate predicted by the changes in gluconeogenesis. Indeed,
both Pdk1 and Pdk4 were highly up regulated in muscle of the Chuvash polycythemia
transgenic mice, which would contribute to decreased glucose oxidation and increased
lactate production through the inhibition of pyruvate dehydrogenase. Similar up regulation
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of PDK1 and PDK4 has also been reported in humans with Chuvash polycythemia [15]. All
of these changes are consistent with the improved glucose tolerance in Chuvash
polycythemia mice being related both to decreased hepatic glucose production and increased
glucose utilization by skeletal muscle.
Altered regulation of the beta islet cells of the pancreas is another potential mechanism for
reduced glucose concentrations in Chuvash polycythemia but it was not explored in humans
in this study. In the Chuvash polycythemia mice model, fasting glucose levels were
significantly lower than in wild types. Normally, lower fasting glucose levels would trigger
lower insulin levels. Fasting insulin levels, however, did not differ between the groups. This
suggests that the Chuvash polycythemia model exhibits augmented insulin secretion (i.e.
enhanced stimulus-secretion coupling), enhanced insulin sensitivity, or a combination of the
two. Consistent with augmented fasting insulin secretion in the Chuvash polycythemia mice,
enhanced HIF-1 activity in mice with homozygous deletion of VHL results in stimulation of
basal rates of glycolysis and therefore basal ATP production in pancreatic β-cells, in turn
resulting in higher fasting insulin levels.[22] Conversely, mice engineered to lack HIF-1β in
pancreatic β-cells exhibited impaired insulin secretion and changes in the islet gene
expression resembling that of human diabetic islets [23, 24]. When glucose-challenged,
however, the mice with homozygous deletion of VHL exhibit impaired glucose-stimulated
insulin secretion because of decreased rates of glucose oxidation [19, 22, 25]. This effect by
itself would be expected to lead to higher glucose excursions after glucose challenge in the
Chuvash polycythemia mice, and instead the opposite was observed, suggesting that any
effects of the VHL mutation on insulin secretion are balanced by the effects of HIF-1 to
decrease glucose production and enhance glucose utilization, as described above. The
situation may be even more complex, in that decreased levels of HIF-1 have also been
associated with impaired β-cell function, and increasing HIF-1 levels by inhibiting
degradation of HIF-1α through iron chelation improves insulin secretion and glucose
tolerance in mice fed a high-fat diet [26]. Thus, it has been proposed that there may be a
dose-response curve for the effect of HIF-1 on β-islet cell function, with deletion of HIF-1α
being deleterious, with mild increases of HIF-1 being beneficial, and with very high levels
also being deleterious [26].
The increased glycerol level observed in metabolomic analysis may reflect increased
lipolysis and is consistent with the trend toward increased serum triglycerides. Hypoxia is
known to increase lipolysis [27] but fat anabolic pathways are also up-regulated in hypoxia,
mediated at least in part by up regulation of the transcription factors PPARγ and SREBP-1
[28-30]. Thus, the effects of the VHLR200W mutation on lipid metabolism may be
pleiotropic and require further study. The increases in citrate, phosphate, and urea levels in
metabolomics analysis are at present of unknown significance or mechanism. A speculation
that is consistent with known effects of hypoxic signaling is that higher citrate in the
VHLR200W population could reflect increased glycolysis and delivery of pyruvate to the
TCA cycle [9]. We did observe increased expression of Glut1, although the net effect of
increased production of pyruvate on increased TCA cycle activity would be dampened by
the observed increases in Pdk1 and Pdk4 that were seen in the skeletal muscle of Chuvash
polycythemia mice.
Our study has some limitations. First, the blood glucose, cholesterol, triglyceride and
metabolomics levels obtained from the VHLR200W homozygotes and controls were random
rather than fasting. Random levels can be altered by consumption of food, especially high
fat and or carbohydrate content, and therefore may not be the best indicators for glucose or
lipid metabolism. Second, the type of diet, the degree of physical activity and having a first-
degree family member with diabetes mellitus are factors that might affect glucose tolerance
in both VHLR200W homozygotes as well as in controls. We have not adjusted our results for
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these variables. Third, a number of factors not specifically addressed by this study might
affect hemoglobin A1c levels, such as blood transfusions [31], hemolysis [32], chronic renal
insufficiency [33], severe hypertriglyceridemia [34], chronic alcohol consumption [35]. In
our cohort, none of the participants had received blood transfusion and there was no
difference in alcohol consumption between the two groups. There is no evidence that
Chuvash polycythemia subjects have lower red cell survival. There were trends to lower
rather than higher BUN and creatinine concentrations in VHLR200W homozygotes. The
serum triglyceride level tended to be higher in the VHLR200W homozygotes compared to
controls, but nevertheless the glycosylated hemoglobin levels were lower in the VHLR200W
homozygotes.
In conclusion, in this study we report that VHL 598C>T homozygosity is associated with
lower glucose concentrations and lower glycosylated hemoglobin (HbA1c) levels indicating
tighter glucose control in individuals with Chuvash polycythemia compared to controls and
suggesting a possible role for manipulation of HIF expression as a means to treat diabetic
patients.
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Figure 1.
a. Distribution of random serum glucose concentration in VHL wildtype subjects and
VHLR200W homozygotes. The median and interquartile ranges were 89 (81-106) mg/dL in
VHL wildtype subjects compared to 75 (56-91) mg/dL inVHLR200W homozygotes. b.
Distribution of hemoglobin A1c in VHL wildtype subjects and VHLR200W homozygotes.
The median and interquartile ranges were 4.1 (3.3-4.6) % in VHL wildtype subjects
compared to 3.2 (1.3-3.6) % in VHLR200W homozygotes. c. Relationship of hemoglobin
A1c level (vertical axis) to random serum glucose concentration. A significant positive
correlation was observed: r = 0.53, P <0.0001.
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Figure 2.
a. Glucose tolerance testing in Chuvash polycythemia (CP) mice and C57BL6 wild type
(WT) controls. Mice (4-10 per group, aged 3-8 months and age-matched across groups) had
fasting glucose tolerance tests performed. Shown are the mean values ±SEM, with the error
bars in most cases hidden within the data points. By panel data analysis, the values for CP
were significantly different compared to WT (P <0.0001). b. Despite the lower fasting
glucose values, insulin levels did not differ between the Chuvash polycythemia and wildtype
mice (Chuvash polycythemia males, 0.54 ± 0.05 ng/ml, wildtype males 0.55 ±0.10 ng/ml, P
=0.96; Chuvash polycythemia females 0.34 ± 0.05, wildtype females 0.31 ± 0.04 ng/ml, P =
0.66).
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Table 1
Distribution of variables in controls and Chuvash polycythemia patients. Results are in
median (interquartile range) unless otherwise indicated
Controls
N=52
VHLR200W
homozygotes,
N=88
P value
Age (year) 50 (39-60) 42 (33-52) 0.005
Female gender, no (%) 34 (65%) 50 (57%) 0.3
Phlebotomy in last year, no (%) 0 45 (51%) <0.0001*
Smoking, no (%) 6 (12%) 25 (28%) 0.020
Alcohol drinking, no (%) 9 (17%) 16 (18%) 0.9
Systolic blood pressure (mm Hg) 126 (118-145) 118 (109-127) 0.005
Diastolic blood pressure (mm Hg) 84 (78-90) 80 (75-85) 0.045
BMI (kg/m2) 24.5 (22.3-27.5) 22.6 (20.2-25.2) 0.004
Hemoglobin (mg/dL) 12.8 (11.8-14.0) 17.8 (15.7-19.7) <0.0001*
WBC (×1000/uL) 6.5 (5.6-7.2) 5.5 (4.4-7.2) 0.0008*
Platelets (×1000/uL) 250 (213-292) 213 (163-267) 0.001*
Creatinine (mg/dL) 0.7 (0.6-0.7) 0.6 (0.6-0.8) 0.14
Phosphate (mg/dL) 3.6 (3.0-4.1) 3.4 (3.0-3.8) 0.2
Triglyceride (mg/dL) 109 (76-174) 137 (101-201) 0.030
Cholesterol (mg/dL) 190 (170-211) 170 (145-199) 0.006
Ferritin (ng/mL) 54 (25-115)1 11 (6-22)2 <0.0001*
1
n=50
2
n=75
*Significant after adjustment for Bonferroni correction.
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Table 2
Pearson correlation of serum glucose concentration and hemoglobin A1c percent with
selected clinical variables
Controls VHLR200W homozygotes
Glucose
r (P)
(N = 52)
HbA1c
r (P)
(N = 41)
Glucose
r (P)
(N = 88)
HbA1c
r (P)
(N = 62)
Age (year) 0.25 (0.07) 0.39 (0.012) 0.22 (0.036) 0.22 (0.08)
Female gender, no (%) 0.01 (0.9)* −0.31 (0.051)* 0.10 (0.4)* 0.0*
Smoking, no (%)
−0.07 (0.6)* 0.20 (0.2)* −0.19 (0.07)* −0.24 (0.06)*
Alcohol drinking, no (%)
−0.10 (0.5)* 0.14 (0.4)* −0.07 (0.5)* −0.11 (0.4)*
Systolic blood pressure
(mm Hg) 0.24 (0.08) 0.45 (0.003)** 0.27 (0.010) 0.12 (0.3)
Diastolic blood pressure
(mm Hg) 0.23 (0.10) 0.46 (0.003)** 0.11 (0.3) 0.01 (0.9)
BMI (kg/m2) 0.24 (0.09) 0.29 (0.07) 0.35 (<0.001)** 0.20 (0.11)
Hemoglobin (mg/dL)
(natural log) 0.03 (0.8) 0.21 (0.18) −0.05 (0.6) 0.17 (0.19)
Creatinine (mg/dL) (square
root) 0.17 (0.2) 0.12 (0.5) 0.06 (0.6) 0.15 (0.3)
Triglyceride (mg/dL)
(natural log) 0.21 (0.13) 0.15 (0.3) 0.26 (0.016) 0.06 (0.6)
Cholesterol (mg/dL)
(square root) 0.30 (0.029) −0.02 (0.9) 0.02 (0.8) −0.01 (0.9)
Ferritin (ng/mL) (natural
log) 0.18 (0.2)1 0.52 (<0.001)2** −0.09 (0.5)3 0.11 (0.4)4
*Spearman rho
1
n=50
2
n=40
3
n=75
4
n=57
**Significant after adjustment for Bonferroni correction.
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Table 3
Predictors of serum glucose concentration and hemoglobin A1c percent by multiple linear
regression
Beta (95% CI) P value
A. Serum glucose concentration (mg/dL, natural log)
(N = 140) *
Homozygous VHLR200W mutation −0.18 (−0.34- −0.02) 0.031
Female gender 0.003 (−0.16- 0.17) 0.9
Age (10 years) 0.05 (−0.01-0.11) 0.094
BMI (kg/M2) 0.02 (0.01- 0.04) 0.009
History of smoking −0.08 (−0.29-0.13) 0.5
B. Hemoglobin A1c (%, square root) (N = 101) **
Homozygous VHLR200W mutation −0.19 (−0.36- −0.02) 0.028
Female gender −0.10 (−0.27-0.07) 0.3
Age (10 years) 0.06 (−0.01- 0.12) 0.072
BMI (kg/M2) 0.02 (0.003- 0.04) 0.046
History of smoking −0.04 (−0.25-0.17) 0.7
*Variables entered into the model were age, gender, VHL mutation, phlebotomy, BMI, smoking, hemoglobin concentration. R-square = 0.18.
**Variables entered into the model were age, gender, VHL mutation, phlebotomy, BMI, smoking, hemoglobin concentration; 2 outliers were
removed. R-square = 0.21
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Table 4
Metabolomic analysis of sera*
Metabolite Controls
(N = 8)
VHLR200W homozygotes
(N = 13)
P value
Glycerol 189 (141-208) 298 (245-459) 0.012
Phosphate 437 (332-518) 576 (500-663) 0.026
Urea 554 (499-732) 1073 (847-1337) 0.004
Citrate 166 (81-204) 355 (194-437) 0.008
*Values reflect median ± interquartile range and are presented as the area under the chromatographic curve.
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Table 5
Relative expression measured by realtime RT-PCR of genes involved in glucose
metabolism in Chuvash polycythemia and control mice
Tissue Gene Control mice
(n = 8, mean ± SEM)
Chuvash polycythemia mice
(n = 8, mean ± SEM)
P value
Liver G6pc 4.32 ± 1.26 0.97 ± 0.21 0.02
Liver Pepck 1.32 ± 0.13 0.99 ± 0.14 0.10
Liver Glutl 1.03 ± 0.11 1.39 ± 0.14 0.07
Liver Glut2 1.30 ± 0.08 1.07 ± 0.04 0.04
Liver Pdk2 0.34 ± 0.04 0.43 ± 0.06 0.36
Muscle Glutl 0.81 ± 0.29 1.18 ± 0.14 0.03
Muscle Glut4 1.27 ± 0.08 1.43 ± 0.18 0.14
Muscle Pdk1 0.86 ± 0.18 1.67 ± 0.43 0.003
Muscle Pdk4 0.50 ± 0.09 1.86 ± 0.24 <0.001
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